Cost of care for colorectal cancer in Ireland: a health care payer perspective

Tilson, Lesley; Sharp, Linda; Usher, Cara; Walsh, Cathal; Whyte, Sophie; O'Ceilleachair, A; C, Stuart; Mehigan, Brian; Kennedy, Michael J.; Tappenden, Paul; Chilcott, Jim; Staines, Anthony; Comber, Harry; Barry, Michael

doi:10.1007/s10198-011-0325-z

Cited by 50 publications

(40 citation statements)

References 42 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We estimated ranges of costs for the initial phase of care stratified by early (UICC I and II) versus late stages (UICC III and IV), making assumptions on the distribution of CRC cases in Germany [12] and on the costs of the initial phase of care for early relative to late stages based on recent reports from other countries [13]–[16]. The formula to derive these estimates is explained in the Appendix S1 .…”

Section: Methodsmentioning

confidence: 99%

Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany

et al. 2014

View full text Add to dashboard Cite

BackgroundThe cost of colorectal cancer (CRC) treatment is a crucial parameter to inform cost-effectiveness analyses on CRC screening but it is not readily available and therefore often lacking. We aimed to elaborate and exemplify a pragmatic approach to estimate CRC treatment cost based on health insurance data from Germany.MethodsWe included two groups of persons who were continuously health-insured between 2005–2010: A) Cases: Persons with a hospital discharge diagnosis of CRC (ICD C18–C20) between 2007–2010 and no such a diagnosis between 2005–2006 (to focus on incident CRC cases); B) Controls: Persons without a diagnosis of CRC during the observation period, matched to CRC cases by age and sex (matching factor: 1∶5). We considered in-patient, out-patient and drug costs and calculated incremental costs as the difference in means between cases and controls. We divided costs into three phases of care (initial, intermediate and end-of-life phase).ResultsThe initial, the intermediate and the end-of-life phase included 12,792, 5,280, and 3,779 CRC cases, respectively, and 63,960, 26,400, and 18,895 controls. The mean incremental costs – annualized for each phase – were €26,000, €2,300, and €51,700, respectively. The costs of the initial phase of care were higher for rectal than for colon cancer. Annualized stage-specific cost estimates ranged from €15,000 to €21,300 for early stages and from €29,800 to €35,000 for late stages.ConclusionThis pragmatic and feasible approach provided plausible estimates of CRC treatment costs in Germany; being transferable to other settings, it may thus facilitate to weigh up potential savings in treatment costs against the resources required for CRC control programs in various countries.

show abstract

Section: Methodsmentioning

confidence: 99%

Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany

et al. 2014

View full text Add to dashboard Cite

show abstract

“…1 In 2008, it was estimated that there were 1,233,000 incident cases of CRC diagnosed worldwide: 663,000 new cases diagnosed in men and 570,000 new cases in women, and almost 60% of the cases occurred in developed regions. 2 Additionally, the medical costs associated with the diagnosis and treatment of CRC patients are substantial, 1,[3][4][5][6][7] which undoubtedly has become a significant economic burden on the countries and the families with CRC patients. Compared with matched patients with no cancer, total monthly costs were $14,585 higher for metastatic CRC patients, which was driven by higher inpatient ($7,546) and outpatient ($6,749) care.…”

Section: What Is Already Known About This Subjectmentioning

confidence: 99%

Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer

Seal

Sullivan²,

Ramsey³

et al. 2013

JMCP

View full text Add to dashboard Cite

show abstract

“…Moreover, systematic colorectal cancer screening is cost-effective as it lowers global healthcare costs in comparison with no screening (6)(7)(8). Average-risk individuals are recommended to be tested at regular intervals above the age of 50 by either gFBOT, fecal immunochemical test, colonoscopy, or sigmoidoscopy (3).…”

Section: Introductionmentioning

confidence: 99%

Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer

Ciarloni¹,

Ehrensberger²,

Imaizumi³

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: A blood test for early detection of colorectal cancer is a valuable tool for testing asymptomatic individuals and reducing colorectal cancer-related mortality. The objective of this study was to develop and validate a novel blood test able to differentiate patients with colorectal cancer and adenomatous polyps (AP) from individuals with a negative colonoscopy.Experimental Design: A case-control, multicenter clinical study was designed to collect blood samples from patients referred for colonoscopy or surgery. Predictive algorithms were developed on 75 controls, 61 large AP (LAP) !1 cm, and 45 colorectal cancer cases and independently validated on 74 controls, 42 LAP, and 52 colorectal cancer cases (23 stages I-II) as well as on 245 cases including other colorectal findings and diseases other than colorectal cancer. The test is based on a 29-gene panel expressed in peripheral blood mononuclear cells alone or in combination with established plasma tumor markers.Results: The 29-gene algorithm detected colorectal cancer and LAP with a sensitivity of 79.5% and 55.4%, respectively, with 90.0% specificity. Combination with the protein tumor markers carcinoembryonic antigen (CEA) and CYFRA21-2 resulted in a specificity increase (92.2%) with a sensitivity for colorectal cancer and LAP detection of 78.1% and 52.3%, respectively.Conclusions: We report the validation of a novel blood test, Colox Ò , for the detection of colorectal cancer and LAP based on a 29-gene panel and the CEA and CYFRA21-1 plasma biomarkers. The performance and convenience of this routine blood test provide physicians a useful tool to test average-risk individuals unwilling to undergo upfront colonoscopy.

show abstract

Cost of care for colorectal cancer in Ireland: a health care payer perspective

Cited by 50 publications

References 42 publications

Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany

Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany

Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer

Development and Clinical Validation of a Blood Test Based on 29-Gene Expression for Early Detection of Colorectal Cancer

Contact Info

Product

Resources

About